Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.56 |
| ▸ | CA1 | P00915 | 3/20 | 0.56 |
| ▸ | CA2 | P00918 | 3/20 | 0.56 |
| ▸ | CA7 | P43166 | 3/20 | 0.56 |
| ▸ | CA9 | Q16790 | 3/20 | 0.56 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.56 |
| ▸ | NPC1 | O15118 | 3/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | ESR1 | P03372 | 1/20 | 0.51 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10746855 | 0.80 | MAPT (0.62) | CA12CA1CA2CA7CA9 | |
| SCHEMBL2247476 | 0.80 | NPC1 (0.59) | CA12CA1CA2CA7CA9 | |
| SCHEMBL3437613 | 0.80 | NPC1 (0.63) | CA12CA1CA2CA7CA9 | |
| SCHEMBL12201007 | 0.79 | ADORA3 (0.50) | NPC1RAB9AHTTALDH1A1HPGD | |
| SCHEMBL15500971 | 0.79 | ADORA3 (0.45) | CA12CA1CA2CA7CA9 | |
| SCHEMBL3268718 | 0.79 | CA12 (0.54) | CA12CA1CA2CA7CA9 | |
| SCHEMBL541988 | 0.79 | NPC1 (0.54) | CA12CA1CA2CA7CA9 | |
| SCHEMBL11204913 | 0.78 | CA12 (0.57) | CA12CA1CA2CA7CA9 | |
| SCHEMBL1458735 | 0.78 | ALDH1A1 (0.58) | CA12CA1CA2CA7CA9 | |
| SCHEMBL21129694 | 0.77 | ADORA3 (0.43) | CA12CA1CA2CA9NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2297133-B1 | 1, 2 DISUBSTITUTED HETEROCYCLIC COMPOUNDS | FORUM PHARMACEUTICALS INC (US) | 2017-09-13 | — | — | EP | disclosed |
| EP-2297133-B1 | 1, 2 DISUBSTITUTED HETEROCYCLIC COMPOUNDS | FORUM PHARMACEUTICALS INC (US) | 2017-09-13 | — | — | EP | disclosed |
| US-9265767-B2 | 1,2-disubstituted heterocyclic compounds | FORUM PHARMACEUTICALS INC. (US) | 2016-02-23 | — | — | US | disclosed |
| US-9265767-B2 | 1,2-disubstituted heterocyclic compounds | FORUM PHARMACEUTICALS INC. (US) | 2016-02-23 | — | — | US | disclosed |
| US-20150274706-A1 | 1,2-DISUBSTITUTED HETEROCYCLIC COMPOUNDS | FMR LLC | 2015-10-01 | — | — | US | disclosed |
| US-20150274706-A1 | 1,2-DISUBSTITUTED HETEROCYCLIC COMPOUNDS | FMR LLC | 2015-10-01 | — | — | US | disclosed |
| US-8933074-B2 | 1,2-disubstituted heterocyclic compounds | FORUM PHARMACEUTICALS INC. (US) | 2015-01-13 | — | — | US | disclosed |
| US-8933074-B2 | 1,2-disubstituted heterocyclic compounds | FORUM PHARMACEUTICALS INC. (US) | 2015-01-13 | — | — | US | disclosed |
| US-20140011808-A1 | 1,2-DISUBSTITUTED HETEROCYCLIC COMPOUNDS | FMR LLC | 2014-01-09 | — | — | US | disclosed |
| US-20140011808-A1 | 1,2-DISUBSTITUTED HETEROCYCLIC COMPOUNDS | FMR LLC | 2014-01-09 | — | — | US | disclosed |
| US-8466148-B2 | 1,2-disubstituted heterocyclic compounds | ENVIVO PHARMACEUTICALS, INC. (US) | 2013-06-18 | — | — | US | disclosed |
| US-8466148-B2 | 1,2-disubstituted heterocyclic compounds | ENVIVO PHARMACEUTICALS, INC. (US) | 2013-06-18 | — | — | US | disclosed |
| US-20120232265-A1 | 1,2-Disubstituted Heterocyclic Compounds | ENVIVO PHARMACEUTICALS, INC. | 2012-09-13 | — | — | US | disclosed |
| US-8071595-B2 | 1,2-disubstituted heterocyclic compounds | ENVIVO PHARMACEUTICALS, INC. (US) | 2011-12-06 | — | — | US | disclosed |
| US-8071595-B2 | 1,2-disubstituted heterocyclic compounds | ENVIVO PHARMACEUTICALS, INC. (US) | 2011-12-06 | — | — | US | disclosed |
| EP-2297133-A1 | 1, 2 DISUBSTITUTED HETEROCYCLIC COMPOUNDS | Envivo Pharmaceuticals, Inc. (US) | 2011-03-23 | — | — | EP | disclosed |
| US-20100137317-A1 | 1,2-Disubstituted Heterocyclic Compounds | ENVIVO PHARMACEUTICALS, INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100137317-A1 | 1,2-Disubstituted Heterocyclic Compounds | ENVIVO PHARMACEUTICALS, INC. (US) | 2010-06-03 | — | — | US | disclosed |
| WO-2009158393-A1 | 1, 2 DISUBSTITUTED HETEROCYCLIC COMPOUNDS | ENVIVO PHARMACEUTICALS, INC. (US) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232265-A1 | 1,2-Disubstituted Heterocyclic Compounds | PDE12, PDE7A, PDE10A | CA12 4346/4885CA1 1758/4885CA2 2855/4885 |
| US-20140011808-A1 | 1,2-DISUBSTITUTED HETEROCYCLIC COMPOUNDS | PDE12, PDE7A, PDE10A | CA12 4346/4885CA1 1758/4885CA2 2855/4885 |
| US-20150274706-A1 | 1,2-DISUBSTITUTED HETEROCYCLIC COMPOUNDS | PDE12, PDE7A, PDE10A | CA12 4346/4885CA1 1758/4885CA2 2855/4885 |
| US-20100137317-A1 | 1,2-Disubstituted Heterocyclic Compounds | PDE12, PDE7A, PDE10A | CA12 4346/4885CA1 1758/4885CA2 2855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.